ARGNF:OTC-argenx SE (USD)

COMMON STOCK | | OTC

Last Closing Price

USD 273.94

Change

0.00 (0.00)%

Market Cap

USD 19.08B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


argenx SE (ARGNF) Stock Analysis:
Based on the argenx SE stock forecasts from 0 analysts, the average analyst target price for argenx SE is not available over the next 12 months. argenx SE’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of argenx SE is Very Bearish, which is based on 0 positive signals and 1 negative signals. At the last closing, argenx SE’s stock price was USD 273.94. argenx SE’s stock price has changed by +0.00 % over the past week, -4.48 % over the past month and +13.14 % over the last year.

About

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; imm ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-03 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BTHI Big Time Holdings, Inc

N/A

USD151.65B N/A N/A
ERGN Ergo Science Corporation

N/A

USD55.23B N/A N/A
WOLTF Wolters Kluwer N.V

N/A

USD30.84B 37.48 N/A
STMZF Scottish Mortgage Investment T..

-0.70 (-3.65%)

USD29.39B 3.75 N/A
MRVGF Mirvac Group

+0.26 (+13.23%)

USD24.50B 11.68 24.47
FYRTF FamilyMart Co., Ltd

N/A

USD24.28B 60.20 N/A
EPOKF Epiroc AB (publ)

N/A

USD23.71B 19.70 N/A
ETTYF Essity AB (publ)

N/A

USD22.58B 26.92 N/A
ZLDSF Zalando SE

N/A

USD22.24B 74.07 N/A
EPKAF Epiroc AB (publ)

N/A

USD20.70B 18.20 N/A

ETFs Containing ARGNF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification ()
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.33% N/A N/A 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.33% N/A N/A 37% F
Trailing 12 Months  
Capital Gain 13.14% N/A N/A 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.14% N/A N/A 52% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 36.54% N/A N/A 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 36.54% N/A N/A 65% D
Risk Return Profile  
Volatility (Standard Deviation) 48.42% N/A N/A 50% F
Risk Adjusted Return 75.45% N/A N/A 91% A-
Market Capitalization 19.08B N/A N/A 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
()
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -55.10 N/A N/A 93% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -14.14% N/A N/A 28% F
Return on Invested Capital -0.53% N/A N/A 42% F
Return on Assets -4.36% N/A N/A 37% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.76 N/A N/A 55% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.